SYRS News and Press, Syros Pharmaceuticals Inc. From 05/07/19

SY-1365 Currently in Phase 1 Clinical Trial in Relapsed and Treatment-Resistant Ovarian and Breast Cancer Patients Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the online publication of a new manus...

Syros Pharmaceuticals, Inc. (SYRS) Q1 2019 Earnings Conference Call May 01, 2019 8:30 AM ET Company Participants Naomi Aoki - Vice President of Corporate Communications & Investor Relations Nancy Simonian - Chief Executive Officer Joe Ferra - Chief Financial Officer David R...

Syros Pharmaceuticals (NASDAQ: SYRS ): Q1 GAAP EPS of -$0.49 beats by $0.07 . More news on: Syros Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Successfully Completed $70 Million Financing On Track for Multiple Data Readouts for Clinical-Stage Programs in 2019 and 2020 Management to Host Conference Call at 8:30 a.m. ET Today Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control ...

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, May 1, 2019 to rep...

Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, has closed concurrent underwritten public offerings resulting in proceeds of approximately $70 million. According to the update, the offerings consist of 8,667,333 of its common...

"Purgatory is hell with hope. ” ― Philip José Farmer The biotech sector is off to a very tough start this Wednesday in what feels like a lot of algorithmic trading as the market is flat, and there is not a lot of news around the sector to account for the drop. Just befo...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a key opinion leader (KOL) breakfast symposium focused on the unmet need, treatment landscape and opportunities for selective cyclin-dependent...

Syros Pharmaceuticals ( SYRS ) has not been doing well in the market since it peaked at $24.31 per share on July 24, 2017. Excitement over some early preclinical- and clinical-stage results has died down, and two cash raises have pointed out the dilution downside potential of poorly capitalize...

Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the closing of its previously announced concurrent underwritten public offerings of (i) 8,667,333 shares of its common stock and accompanying Class A warrants ...